RFA-TR-22-011: Emergency Awards: HEAL Initiative – Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome(R21 Clinical Trial Not Allowed)
First application due date: February 28, 2022 with additional due dates later in the year and in 2023.
The purpose of this funding opportunity announcement (FOA) is to support early-stage research projects focusing on the identification of new druggable targets for pain, opioid use disorder (OUD) and/or overdose (OD) within the understudied druggable proteome. This FOA is part of the NIH Helping to End Addiction Long-Term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.
Awards will support early-stage research to increase our knowledge of understudied proteins of the druggable proteome and enable the scientific community to identify and validate new targets for pain, OUD and/or OD. These awards will support generation of preliminary data and tools around eligible understudied protein(s) identified by the HEAL program with the intent of elucidation the function of these proteins in the context of pain, OUD and/or OD and obtaining sufficient preliminary data and/or research resources for subsequent R01 applications and/or drug discovery/development projects.
The full list of eligible targets can be found here. The list of eligible targets will not change while this FOA is active. ONLY APPLICATIONS THAT FOCUS ON PROTEINS LISTED ON THIS LIST, AS WELL AS MEETING THE RESPONSIVENESS CRITERIA LISTED IN THE FOA, WILL BE CONSIDERED RESPONSIVE.
Applicants should provide the Uniprot number for the protein(s) that will be the focus of their application at the top of page one of their Research Plan, which will allow NIH to quickly identify those projects that are responsive to this FOA.
Learn more: https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-011.html